Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
Targeting Notch in oncology: the path forward
Notch signalling is involved in many aspects of cancer biology, including angiogenesis,
tumour immunity and the maintenance of cancer stem-like cells. In addition, Notch can …
tumour immunity and the maintenance of cancer stem-like cells. In addition, Notch can …
Management of salivary gland malignancy: ASCO guideline
PURPOSE To provide evidence-based recommendations for practicing physicians and
other healthcare providers on the management of salivary gland malignancy. METHODS …
other healthcare providers on the management of salivary gland malignancy. METHODS …
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …
The evolving landscape of salivary gland tumors
Salivary gland cancers are a rare, histologically diverse group of tumors. They range from
indolent to aggressive and can cause significant morbidity and mortality. Surgical resection …
indolent to aggressive and can cause significant morbidity and mortality. Surgical resection …
Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets
Purpose: Salivary gland adenoid cystic carcinoma (ACC) has heterogeneous clinical
behavior. Currently, all patients are treated uniformly, and no standard-of-care systemic …
behavior. Currently, all patients are treated uniformly, and no standard-of-care systemic …
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors
Purpose: In this first-in-human, Phase 1, open-label, multicenter study, we evaluated JNJ-
64619178, a selective and potent PRMT5 inhibitor, in patients with advanced malignant …
64619178, a selective and potent PRMT5 inhibitor, in patients with advanced malignant …
Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease
L Di Villeneuve, IL Souza, FDS Tolentino… - Frontiers in …, 2020 - frontiersin.org
Salivary gland carcinomas (SGC) account for less than 5% of head and neck malignant
neoplasms, further subcategorized in over 20 histological subtypes. For the most part …
neoplasms, further subcategorized in over 20 histological subtypes. For the most part …
The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype
Purpose: Salivary gland carcinomas (SGC) are rare, aggressive cancers with high rates of
recurrence and distant metastasis. These factors, and a lack of active systemic therapies …
recurrence and distant metastasis. These factors, and a lack of active systemic therapies …
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling
Adenoid cystic carcinoma (ACC) is an aggressive salivary gland malignancy with limited
treatment options for recurrent or metastatic disease. Due to chemotherapy resistance and …
treatment options for recurrent or metastatic disease. Due to chemotherapy resistance and …